We have used polymerase chain reaction (PCR) ampli®cation of tandem repeats to study the pattern of allelic loss on chromosome X11.2-q12 in borderline and invasive epithelial ovarian tumors. Using eight microsatellite markers spanning Xq11.2-q12, 41 borderline and 65 invasive ovarian tumors, together with their corresponding normal tissues, were analysed. The highest percentage of loss of heterozygosity (LOH) was observed at the DXS1194 locus in borderline tumors (four of 16 informative cases, 25%) and at the androgen receptor (AR) locus in invasive epithelial ovarian tumors (18 of 47 informative cases, 38%). X chromosome activation studies performed in cases with LOH at the AR locus showed that the allelic loss at the AR locus is not con®ned to the inactive allele. A one centimorgan region including the AR locus and¯anked by the primers DXS1161 and PGK1P1 was identi®ed as the smallest common loss region in both borderline and invasive epithelial ovarian tumors.
Introduction
Borderline ovarian tumors, also known as ovarian epithelial tumors of low malignant potential, are a distinct entity within the classi®cation of ovarian neoplasms. These tumors have a histological appearance and biologic behavior which are intermediate between benign and frankly malignant ovarian neoplasms (Scully, 1982) . While these tumors are cytologically malignant with evidence of cellular pleomorphism, they do not exhibit any stromal invasion. A prolonged survival is expected with these tumors even without the use of chemotherapy (Bostwick et al., 1986; Barakat, 1994; Leake, 1992; Leake et al., 1992; Casey et al., 1993) .
Genetic studies have been used to understand the biology of ovarian cancers. Loss of heterozygosity (LOH) studies have been used to detect allelic losses of speci®c chromosomes in order to identify possible tumor suppressor genes which may be relevant to the development of ovarian cancer. While many of these studies have focused on invasive epithelial ovarian carcinomas, only a few studies have examined genetic alterations of borderline ovarian tumors. These studies have been unable to detect any signi®cant level of genetic alterations speci®c to borderline tumors emphasizing the possible separate pathogenesis of these tumors (Rodabaugh et al., 1995b; Wertheim et al., 1994; Tangir et al., 1996; Rodabaugh et al., 1995a; Dodson et al., 1993; Kim et al., 1994) . Recently, Zheng et al. have demonstrated that 50% of informative borderline tumors (eight of 16 informative cases) and approximately 44% of high grade IEOC displayed LOH at the androgen receptor (AR) locus in the proximal portion of chromosome Xq (Cheng et al., 1996) . These results suggest that LOH in this region may be important for the development of borderline tumors and high grade invasive epithelial ovarian carcinomas.
In this study, we report the construction of a detailed deletion map of chromosome Xq11.2-q12 from 41 borderline tumors and 65 invasive epithelial ovarian carcinomas using eight microsatellite markers in an eort to more accurately localize a region(s) which may be involved in the development of borderline ovarian tumors and invasive EOC.
Results

LOH in Xq11.2-Xq12
A set of eight microsatellite markers spanning the region from Xq11.2 to Xq12 (Figure 1 ) was used to perform the LOH study on 41 borderline ovarian tumors and 65 invasive epithelial ovarian carcinomas with various stages and grades. All cases showed interstitial LOH for several of the microsatellite loci tested. LOH aecting at least one locus was observed in 29% of the borderline tumors (12 of 41 informative cases) and 34% of the invasive epithelial carcinomas (22 of 65 informative cases). The LOH results derived from paran embedded tissue and frozen materials were not dierent statistically, and thus were combined in the analysis of both borderline ovarian tumors and invasive epithelial ovarian carcinomas. Figure 2 shows autoradiographs of ®ve borderline tumor cases depicting LOH at the AR locus in the tumor lane with the normal control in the adjacent lane.
LOH in borderline tumors
The percentage of tumors with allelic loss at each locus for borderline tumors is shown in Figure 1 . The highest percentage of LOH was observed at DXS1213 (four of 16 informative cases, 25%) and at the AR locus (seven of 30 informative cases, 23%). All other loci showed a much lower percentage of LOH. A one centimorgan region including the AR locus and¯anked by the primers DXS1161 and PGK1P1 was identi®ed as the smallest common loss region using selected cases which showed restricted LOH patterns (Figure 3 ). Cases B5, 466, and 543 speci®cally show LOH at the AR locus and no LOH at the¯anking primers DXS1161 and PGK1P1.
LOH in invasive epithelial ovarian carcinomas
Similar to the borderline tumors, the AR locus showed the highest percentage of allelic loss (18 of 47 informative cases, 38%, Figure 1 ). However, thē anking primers showed a higher percentage of LOH in the invasive epithelial ovarian carcinomas as compared to the borderline tumors. Five cases 351, 384, 528 and 545) showed allelic loss at almost all the loci suggesting that these samples had LOH in the whole Xq11.2-q12 region. Therefore, these cases were not informative for the localization of the smallest region of allelic loss. The remaining 17 cases showed restricted LOH patterns which allowed us to de®ne the smallest common loss region. This region, approximately one centimorgan, is located between the markers DXS1161 and PGK1P1. The identi®cation of this region was based on the study of cases 315, 317, 416 and 490 (Figure 4 ).
LOH with respect to grade, stage and histological type
Clinicopathological characteristics of the tumors were analysed based on allelic loss at the AR locus (Table  1) . No signi®cant dierence was observed between LOH rate at the androgen receptor locus and stage or tumor type for borderline tumors. Similar analysis for invasive epithelial ovarian carcinomas did reveal a statistically signi®cant dierence of allelic loss at the AR locus for Stage III/IV tumors (P=0.04) and serous tumors (P=0.02). Comparison of LOH rate at the AR locus between borderline tumors (23%), low grade carcinomas (32%), and high grade carcinomas (53%) did not reveal any statistical dierence (P=0.10), though a trend towards a greater frequency of LOH at the AR locus with less dierentiated tumors was observed.
No selective loss of the inactive allele at the AR locus
Selected paired normal and tumor DNA from cases which showed LOH at the AR locus were subjected to HpaII restriction enzyme digestion to evaluate whether the lost allele is active or inactive. After digestion, the remaining allele of cases 324, 336, 490, 528, 545 and 558 disappeared after digestion suggesting that in these cases the inactive AR allele was lost ( Figure 5a ). In contrast, the remaining allele of cases 332, 384, and 386 could still be observed, suggesting that the active AR allele was lost in these cases ( Figure 5b ). When DNA from normal tissue from cases 324, 332, 386, 490, 528, and 558 were digested with HpaII, a skewing pattern of the two AR alleles was observed. This was particularly evident in case 386 suggesting a relatively selective X- The AR allele was not totally deleted in a majority of cases that showed LOH
To evaluate whether loss of heterozygosity observed at the AR locus was due to total allelic deletion or deletion with the replacement by the remaining allele, we performed multiplex PCR. Primers D7S523 and D11S1334 did not exhibit LOH at the AR locus for these selected cases, and thus were used as internal standards. After normalization of the intensity of the alleles generated by the two control primer sets, the intensity of the retained AR allele in the tumor tissue of cases 332, 324 and 558 was found to be comparable to that of the corresponding normal tissue (Figure 6 ). In contrast, the intensity of the retained AR allele in 
Discussion
We have identi®ed a one centimorgan smallest common region of allelic loss on Xq11.2-q12 in borderline tumors and invasive epithelial ovarian carcinomas. This common region of loss contains the AR locus and is¯anked by the primers DXS1161 and PGKP1. We also observed a higher percentage of LOH at the AR locus for high grade carcinomas when compared to borderline tumors and low grade carcinomas.
We have found a molecular genetic abnormality which is common in borderline tumors, low grade IEOC and high grade IEOC. This genetic alteration may represent an early event in ovarian tumorigenesis, suggesting a continuous spectrum of development similar to the colorectal carcinoma model (Fearon et al., 1990) . Whether ovarian carcinomas develop de novo or by a multistep clonal expansion from preexisting benign tumors is unknown. Evidence that borderline tumors and low grade IEOC appear phenotypically stable over time with no evidence of progression towards a biologically more aggressive lesions support a de novo hypothesis. A recent study of 14 cases of incidentally discovered ovarian carcinomas con®ned to one ovary supports this theory (Bell and Scully, 1994) . Furthermore, studies have shown an absence of a common pattern of genetic alterations between borderline tumors and invasive epithelial ovarian carcinomas suggesting a separate pathogenesis for these tumors (Wertheim et al., 1994; Tangir et al., 1996; Rodabaugh et al., 1995a,b) . However, our data shows similar genetic alterations in borderline tumors and invasive carcinomas with fewer abnormalities in borderline tumors. This suggests that a certain percentage of high grade lesions may have progressed through an earlier, clinically inapparent borderline or lower grade counterpart. This hypothesis is also supported by the identi®cation of a high percentage of K-ras mutations in both BOT and IEOC, particularly in the mucinous subtype .
By using HpaII digestion, we attempted to determine whether the remaining allele is active or not. The relatively CpG-dense promoter of the AR gene subject to X-chromosome inactivation is hypermethylated and, therefore, resistant to digestion with methylation sensitive restriction enzymes such as HpaII (Vogelstein et al., 1987) . Using PCR analysis combined with HpaII digestion, the active and inactive AR alleles can be distinguished (Allen et al., 1992) . These results are important in the interpretation of the LOH data as well as in the construction of a model. If the lost allele is always the active allele, then this is equivalent to inactivation of both alleles, suggesting that the candidate gene in the deleted region is a tumor suppressor gene. On the other hand, if the lost allele is always the inactive allele, the LOH data could ®t either a tumor suppressor gene or proto-oncogene . DNA obtained from the normal (N) and tumor tissue (T) of the same patient was incubated in buer in absence (control) or presence (HpaII+) of methylation-sensitive endonuclease HpaII. All samples were ampli®ed by PCR using primers¯anking the trinucleotide repeat polymorphism and the adjacent HpaII sites in the ®rst exon of the AR gene. The radiolabeled PCR products were loaded onto a 6% polyacrylamide gel and electrophoresed at 1800 V for 2 h model, depending on whether there is reduplication and mutation of the remaining allele. If there is reduplication of the remaining active allele without an inactivating mutation, the net eect of this genetic alteration would be to double the gene dosage. Thus, the candidate gene could be an oncogene with expression of two copies of the gene instead of only one. However, if there is inactivating mutation in the remaining active allele, the candidate gene could still be a tumor suppressor gene. Six out of our nine cases with LOH showed loss of the inactive allele. Of those six cases, four showed duplication of the remaining allele. Thus, these data are inconclusive in determining if the candidate gene is a tumor suppressor gene or an oncogene. It will eventually require the identi®cation of the candidate gene and its mutational analysis before any ®nal conclusion can be drawn. As far as the possibility of the candidate gene(s), there are relatively few known genes in the minimally deleted region. The single highest incidence of LOH is found at the AR locus for both borderline and invasive ovarian tumors, thus making AR a likely candidate gene. The only reported role of the androgen receptor in cancer is in the hormonal response of prostate cancer and male breast cancer (Schoenberg et al., 1994; Newmark et al., 1992; Lobaccaro et al., 1993; Tilley et al., 1996; Taplin et al., 1995) . Ampli®cation of the androgen receptor gene has been found in recurrent hormone-refractory prostate tumors, but not in primary prostate tumors (Visakorpi et al., 1995) . It is not clear whether the androgen receptor could contribute to the oncogenesis of tumor in the female genital tract. Work is now ongoing in our laboratory to search for mutations in the AR gene in ovarian cancer as well as the role of androgens in the growth regulation of both normal ovarian epithelial cells and ovarian cancer cells in vitro.
Materials and methods
Tumor collection and DNA extraction
Surgical specimens of human ovarian tissue were obtained from 73 patients under a protocol approved by the Human Subjects Committee of the Brigham and Women's Hospital. Archival material consisted of 33 paran blocks. The corresponding normal tissues consisted of segments of normal fallopian tube, uninvolved round ligament, or peripheral blood. All histopathologic diagnoses of ovarian epithelial tumors were con®rmed by a gynecologic pathologist. Grade 1 and grade 2 invasive tumors were categorized as low-grade tumors, while highgrade tumors included grade 3 and grade 4 invasive tumors. All tumors were surgically staged according to FIGO criteria (International Federation of Gynecology and Obstetrics, 1987) . DNA was extracted using previously published methods .
PCR and LOH studies
LOH was performed by PCR ampli®cation of tandem repeats located at eight loci on chromosome Xq11.2-q12. The map position and genetic distance between primers are based on the Genethon chromosome X map and a report on the sixth international workshop on X chromosome mapping (Gyapay et al., 1994; Nelson et al., 1995; Weeks et al., 1995) . The dierent loci and their map positions are summarized in Figure 1 . The forward primer of each set was end labeled with gamma 32 P-ATP (ICN, Irvine, CA) and polynucleotide kinase (Boehringer Mannheim, Indianapolis, IN). The reaction mix was then diluted into a ®nal volume of 320.5 ml of primer-PCR mixture containing 40 ml 106PCR Buer (0.1 M Tris-HCl, 0.5 M KCl, pH 8.3), 20 ± 50 ml 4 mM MgCl 2 , 20 ml 1.25 mM dNTP, 2.0 ml (10 units) of Taq Polymerase (Perkins-Elmer Cetus, Norwalk, CT) and 1 ml of each primer. Four ml of this PCR mixture was mixed with each DNA sample. Ampli®cation was carried out using 50 ng of genomic DNA using 35 cycles of PCR with denaturation at 948C for 30 s, annealing at 45 ± 668C for 30 s and extension at 728C for 30 s. PCR products were diluted in 45 ml of loading buer containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol FF (Sigma, St Louis, MO). Three microliters of this mixture was then loaded onto a 6% acrylamide denaturing gel and electrophoresed at a constant 1700 volts. The gel was transferred onto a 3 MM paper, dried and autoradiographed with Kodak X-OMAT AR ®lms for 3 ± 4 h at room temperature. The autoradiographs were then developed and examined for evidence of LOH.
Cases were considered to be informative when heterozygosity was detected in normal tissue samples. LOH was de®ned as a visible reduction of 50% or more in the band intensity of one of the tumors sample allele when compared to the normal tissue control. Homozygous alleles in the normal tissue samples were labeled as uninformative.
X chromosome inactivation studies
Two micrograms of tumor and normal DNA samples from cases with known LOH at the AR locus were digested with 20 units of HpaII restriction endonuclease (Boehringer Mannheim, Indianapolis, IN) in a total volume of 20 ml. Control reactions consisting of normal and tumor DNA samples incubated in the digestion buer without endonuclease were also performed. After digestion overnight at 378C, 1 ml of DNA from each reaction was used as templates for PCR ampli®cation using the AR primers as described above.
Multiplex PCR analysis
Multiplex PCR analysis of microsatellite polymorphism was conducted to determine whether allelic imbalances observed at the AR locus were due to total deletion or deletion with duplication of the homozygous allele. Besides the AR primer set, another primer pair (D7S523 on chromosome 7q or D11S1334 on chromosome 11p) was included in the PCR reaction as an internal control. The control primers were chosen based on their retention of heterozygosity and the size of the microsatellite markers used. The number of PCR cycles were varied between 25 and 35 before an optimal protocol allowed for consistent ampli®cation in repeated assays. Three ml of the PCR mixture was then loaded onto a 6% acrylamide denaturing gel and electrophoresed as described above. A second gel was rerun on diluted samples which showed identical allelic intensities on both normal and tumor samples in the control markers. The allelic intensities of both AR alleles in tumor DNA and normal DNA were then compared and quanti®ed by a densitometer.
Statistical analysis
Comparison of allelic loss frequencies and clinicopathologic parameters was assessed by Chi-Square and Fisher's exact test when an expected cell value was ®ve or less. Statistical signi®cance was considered when P values were less than 0.05.
